Comprehensive Stock Comparison
Compare BlackRock Technology and Private Equity Term Trust (BTX) vs Agios Pharmaceuticals, Inc. (AGIO) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  AGIO | 48.0% revenue growth vs BTX's -81.1% |
| Quality / Margins |  BTX | 87.7% net margin vs AGIO's -9.0% |
| Stability / Safety | AGIO | Beta 0.91 vs BTX's 1.16 |
| Dividends | BTX | 13.1% yield; 1-year raise streak; AGIO pays no meaningful dividend |
| Momentum (1Y) | BTX | +7.1% vs AGIO's -15.0% |
| Efficiency (ROA) | BTX | 1.8% ROA vs AGIO's -29.0%, ROIC 1.4% vs -26.6% |
Who Each Stock Is For
Income & stability
AGIObeta 0.91
Growth exposure
AGIORev growth 48.0%, EPS growth -161.2%, 3Y rev CAGR 56.0%
Long-term compounding (10Y)
AGIO-36.0% 10Y total return vs BTX's -45.8%
Sleep-well-at-night portfolio
AGIOLower volatility, beta 0.91, Low D/E 3.4%, current ratio 11.46x
Defensive / Recession hedge
AGIOBeta 0.91, current ratio 11.46x
Business Model
What each company does and how it makes money
BlackRock Technology and Private Equity Term Trust is a closed-end investment fund that pools investor capital to invest primarily in mid- and small-capitalization growth companies in the technology and healthcare sectors. It generates returns through capital appreciation and dividend income from its equity portfolio, with performance tied to the success of its underlying investments. The fund's key advantage is BlackRock's extensive research capabilities and access to innovative companies that traditional investors might overlook.
Agios Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare genetic diseases related to cellular metabolism. It generates revenue primarily from sales of its lead drug PYRUKYND for pyruvate kinase deficiency — with additional income from research collaborations and milestone payments — while advancing a pipeline of other metabolic therapies. The company's competitive advantage lies in its deep expertise in cellular metabolism science and proprietary platform for targeting metabolic pathways in rare diseases.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
BTX 3AGIO 0BTX4/4 metricsBTX2/3 metricsBTX5/6 metricsBTX leads in 3 of 6 categories — strongest in Financial Metrics and Valuation Metrics. 2 categories are tied.
Financial Metrics (TTM)
AGIO and BTX operate at a comparable scale, with $45M and $41M in trailing revenue. BTX is the more profitable business, keeping 87.7% of every revenue dollar as net income compared to AGIO's -9.0%.
| Metric | BTXBlackRock Technol… | AGIOAgios Pharmaceuti… |
|---|---|---|
| RevenueTrailing 12 months | $41M | $45M |
| EBITDAEarnings before interest/tax | — | -$470M |
| Net IncomeAfter-tax profit | — | -$401M |
| Free Cash FlowCash after capex | — | -$414M |
| Gross MarginGross profit ÷ Revenue | +100.0% | +84.4% |
| Operating MarginEBIT ÷ Revenue | +87.7% | -10.6% |
| Net MarginNet income ÷ Revenue | +87.7% | -9.0% |
| FCF MarginFCF ÷ Revenue | +6.8% | -9.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +43.7% |
| EPS Growth (YoY)Latest quarter vs prior year | — | -111.0% |
Valuation Metrics
| Metric | BTXBlackRock Technol… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Market CapShares × price | $765M | $2.11T |
| Enterprise ValueMkt cap + debt − cash | $765M | $2.11T |
| Trailing P/EPrice ÷ TTM EPS | 38.56x | -3.99x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 21.43x | — |
| Price / SalesMarket cap ÷ Revenue | 18.80x | 9999.00x |
| Price / BookPrice ÷ Book value/share | 0.79x | 1.38x |
| Price / FCFMarket cap ÷ FCF | 2.76x | — |
Profitability & Efficiency
BTX delivers a 1.9% return on equity — every $100 of shareholder capital generates $2 in annual profit, vs $-31 for AGIO.
| Metric | BTXBlackRock Technol… | AGIOAgios Pharmaceuti… |
|---|---|---|
| ROE (TTM)Return on equity | +1.9% | -31.2% |
| ROA (TTM)Return on assets | +1.8% | -29.0% |
| ROICReturn on invested capital | +1.4% | -26.6% |
| ROCEReturn on capital employed | +1.8% | -33.8% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 |
| Debt / EquityFinancial leverage | — | 0.03x |
| Net DebtTotal debt minus cash | $0 | -$49M |
| Cash & Equiv.Liquid assets | — | $89M |
| Total DebtShort + long-term debt | $0 | $40M |
| Interest CoverageEBIT ÷ Interest expense | 2313.25x | — |
Total Returns (with DRIP)
A $10,000 investment in AGIO five years ago would be worth $5,997 today (with dividends reinvested), compared to $5,420 for BTX. Over the past 12 months, BTX leads with a +7.1% total return vs AGIO's -15.0%. The 3-year compound annual growth rate (CAGR) favors BTX at 5.5% vs AGIO's 5.5% — a key indicator of consistent wealth creation.
| Metric | BTXBlackRock Technol… | AGIOAgios Pharmaceuti… |
|---|---|---|
| YTD ReturnYear-to-date | -0.4% | +4.4% |
| 1-Year ReturnPast 12 months | +7.1% | -15.0% |
| 3-Year ReturnCumulative with dividends | +17.5% | +17.4% |
| 5-Year ReturnCumulative with dividends | -45.8% | -40.0% |
| 10-Year ReturnCumulative with dividends | -45.8% | -36.0% |
| CAGR (3Y)Annualised 3-year return | +5.5% | +5.5% |
Risk & Volatility
AGIO is the less volatile stock with a 0.91 beta — it tends to amplify market swings less than BTX's 1.16 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BTX currently trades 87.4% from its 52-week high vs AGIO's 61.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BTXBlackRock Technol… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.16x | 0.91x |
| 52-Week HighHighest price in past year | $7.50 | $46.00 |
| 52-Week LowLowest price in past year | $5.10 | $22.24 |
| % of 52W HighCurrent price vs 52-week peak | +87.4% | +61.7% |
| RSI (14)Momentum oscillator 0–100 | 47.5 | 63.8 |
| Avg Volume (50D)Average daily shares traded | 791K | 893K |
Analyst Outlook
BTX is the only dividend payer here at 13.05% yield — a key consideration for income-focused portfolios.
| Metric | BTXBlackRock Technol… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $41.50 |
| # AnalystsCovering analysts | — | 29 |
| Dividend YieldAnnual dividend ÷ price | +13.1% | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | $0.86 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +12.1% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 21 | Mar 26 | Change |
|---|---|---|---|
| BlackRock Technolog… (BTX) | 100 | 32.74 | -67.3% |
| Agios Pharmaceutica… (AGIO) | 100 | 53.94 | -46.1% |
Agios Pharmaceutica… (AGIO) returned -40% over 5 years vs BlackRock Technolog… (BTX)'s -46%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| BlackRock Technolog… (BTX) | $-640M | $41M | +106.4% |
| Agios Pharmaceutica… (AGIO) | $70M | $54M | -22.7% |
Agios Pharmaceuticals, Inc.'s revenue grew from $70M (2016) to $54M (2025) — a -2.8% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2025 | Change |
|---|---|---|---|
| BlackRock Technolog… (BTX) | 100.1% | 87.7% | -12.4% |
| Agios Pharmaceutica… (AGIO) | -199.1% | -7.6% | +96.2% |
Agios Pharmaceuticals, Inc.'s net margin went from -199% (2015) to -8% (2025).
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| BlackRock Technolog… (BTX) | -2.58 | 0.17 | +106.6% |
| Agios Pharmaceutica… (AGIO) | -5.07 | -7.12 | -40.4% |
Agios Pharmaceuticals, Inc.'s EPS grew from $-5.07 (2016) to $-7.12 (2025).
Chart 5Free Cash Flow — 5 Years
BlackRock Technology and Private Equity Term Trust generated $277M FCF in 2024 (+106% vs 2021). Agios Pharmaceuticals, Inc. generated $-377M FCF in 2025 (+9% vs 2021).
BTX vs AGIO: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is BTX or AGIO a better buy right now?
BlackRock Technology and Private Equity Term Trust (BTX) offers the better valuation at 38.6x trailing P/E, making it the more compelling value choice. Analysts rate Agios Pharmaceuticals, Inc. (AGIO) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BTX or AGIO?
Over the past 5 years, Agios Pharmaceuticals, Inc. (AGIO) delivered a total return of -40.0%, compared to -45.8% for BlackRock Technology and Private Equity Term Trust (BTX). A $10,000 investment in AGIO five years ago would be worth approximately $6K today (assuming dividends reinvested). Over 10 years, the gap is even starker: AGIO returned -36.0% versus BTX's -45.8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BTX or AGIO?
By beta (market sensitivity over 5 years), Agios Pharmaceuticals, Inc. (AGIO) is the lower-risk stock at 0.91β versus BlackRock Technology and Private Equity Term Trust's 1.16β — meaning BTX is approximately 29% more volatile than AGIO relative to the S&P 500.
04Which has better profit margins — BTX or AGIO?
BlackRock Technology and Private Equity Term Trust (BTX) is the more profitable company, earning 87.7% net margin versus -764.0% for Agios Pharmaceuticals, Inc. — meaning it keeps 87.7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BTX leads at 87.7% versus -873.9% for AGIO. At the gross margin level — before operating expenses — BTX leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — BTX or AGIO?
In this comparison, BTX (13.1% yield) pays a dividend. AGIO does not pay a meaningful dividend and should not be held primarily for income.
06Is BTX or AGIO better for a retirement portfolio?
For long-horizon retirement investors, BlackRock Technology and Private Equity Term Trust (BTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.16), 13.1% yield). Both have compounded well over 10 years (BTX: -45.8%, AGIO: -36.0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between BTX and AGIO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: BTX is a small-cap income-oriented stock; AGIO is a mega-cap quality compounder stock. BTX pays a dividend while AGIO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.